Texas is currently home to 4891 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Houston, Dallas, San Antonio and Austin. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)
Recruiting
This study, the first clinical trial of AVZO-1418, aims to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, maximum tolerated dose, and antitumor activity of AVZO-1418 when administered intravenously as a monotherapy and potentially in combination therapy to patients with locally advanced or metastatic epithelial solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/18/2025
Locations: Avenzo Therapeutics Recruiting Site, Dallas, Texas
Conditions: Solid Tumor Cancer, Locally Advanced, Metastatic Solid Tumors, Lung Cancers, Epithelial Tumor
The Neighborhood & Health Study
Recruiting
The objective of The Neighborhood \& Health Study is to use a quasi-experimental mixed-methods approach to assess the impact of living in an agrihood-an agriculturally integrated community. This study follows a longitudinal cohort of residents of a newly developed neighborhood (the Indigo Neighborhood) and a geographically and socio-demographically matched neighborhood (the Elyson Neighborhood), both located in Fort Bend County, Texas, providing a unique opportunity for a natural experiment.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/18/2025
Locations: Elyson Neighborhood, Katy, Texas
Conditions: Healthy Eating, Cardiometabolic Health
A Study to Learn About How the Flu and COVID-19 Vaccines Act in Healthy People
Recruiting
The purpose of this study is to learn about how the flu and COVID vaccines act when given alone or when mixed together. This study is seeking healthy participants aged 18 or older. All participants in this study will receive only 1 shot to their arm, either a flu or COVID vaccine, alone or mixed. Participants will take part in this study for about 6 months, and participants will need to visit the clinical study site at least 4 times.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/18/2025
Locations: Headlands Horizons, LLC dba Headlands Research-Brownsville, Brownsville, Texas
Conditions: Influenza, COVID-19 (Coronavirus Disease 2019)
Behavioral Economic Intervention to Improve HIV Behaviors in Sexual Minority Individuals
Recruiting
This research study is testing a new behavioral therapy called Episodic Future Thinking or EFT can help people reduce drug use and risky sexual behaviors while helping them adhere to their HIV prevention medication (PrEP). Participants will be randomly assigned to one of two groups. One group will receive standard care, which includes counseling on HIV prevention, drug use reduction, and sexual health. The other group will receive standard care plus a new program called Episodic Future Thinking... Read More
Gender:
ALL
Ages:
Between 18 years and 34 years
Trial Updated:
06/18/2025
Locations: University of Texas Health Science Center at San Antonio, San Antonio, Texas
Conditions: HIV Prevention
A Study to Investigate Multiple Sclerosis Relapse Prevention With mRNA-1195 Compared With Placebo in Participants Aged 18 to ≤55 Years
Recruiting
The primary objective of this trial is to evaluate the safety and reactogenicity of mRNA-1195 in participants with multiple sclerosis.
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
06/18/2025
Locations: ANESC Research, El Paso, Texas
Conditions: Multiple Sclerosis
Examination of Nociscan Impact on Discogenic Low Back Pain Surgical Outcomes
Recruiting
This study is looking into how safe and useful NOCISCAN is. NOCISCAN is a software as a Service (SaaS) tool that uses Magnetic Resonance (MR) spectroscopy. Nociscan (instead of 'It') leverages MRS to noninvasively help physicians distinguish between painful and nonpainful discs in the lumbar spine. The randomized controlled trial will compare the blinded and unblinded cohorts and their corresponding surgical outcomes with the Nocigram reports, generated prior to treatment, for each patient."
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
06/18/2025
Locations: Texas Back Institute, Plano, Texas
Conditions: Discogenic Low Back Pain
A Phase 2 Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast Cancer
Recruiting
This is an adaptive Phase 2, open-label, randomized, multi-center study evaluating up to 2 regimens of PCS6422 with capecitabine (Cap) vs. standard dose of Cap alone in patients with advanced or metastatic breast cancer. The goal of the study is to assess the efficacy and safety of PCS6422 + Cap as a treatment option for patients with advanced or metastatic breast cancer who are not eligible for anthracycline- or taxane-containing therapies, or other available therapies, including PD-1 or PARP i... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/18/2025
Locations: Texas Oncology PA (Austin), Austin, Texas
Conditions: Breast Cancer, TNBC - Triple-Negative Breast Cancer, HER2-negative Breast Cancer
A First-In Human (FIH) Trial to Find Out if REGN10597 is Safe and How Well it Works for Adult Participants With Advanced Solid Organ Malignancies
Recruiting
This study is researching an experimental drug called REGN10597 (called "study drug"). The study is focused on patients with certain solid tumors that are in an advanced stage. The aim of the study is to see how safe, tolerable, and effective the study drug is. The study is looking at several other research questions, including: * What side effects may happen from taking the study drug * How much study drug is in the blood at different times * Whether the body makes antibodies against the stu... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/18/2025
Locations: MD Anderson Cancer Center, Houston, Texas
Conditions: Melanoma, Clear-Cell Renal-Cell Carcinoma (ccRCC), Advanced Solid Tumors
A Trial to Learn if Linvoseltamab is Safe and Works in Adults With Relapsed or Refractory Systemic Light Chain Amyloidosis (AL Amyloidosis)
Recruiting
This study is researching an experimental drug called linvoseltamab ("study drug"). This study is focused on patients who have AL amyloidosis that has returned or have failed other therapies and need to be treated again. The study consists of 2 phases (Phase 1 and Phase 2): * In Phase 1, linvoseltamab will be given to a small number of participants to study the side effects of the study drug and to determine the recommended doses of the study drug to be given to participants in Phase 2. * In... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/18/2025
Locations: MD Anderson Cancer Center, Houston, Texas
Conditions: Relapsed/Refractory Systemic Light Chain Amyloidosis
Ultrasound-guided Peripheral Intravenous Catheter Placement in an Oncologic Emergency Department - a Prospective, Randomized Controlled Trial of Catheter Lengths
Recruiting
To learn about the effects of the length of the catheter on the failure and success rate of USIV placement.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/18/2025
Locations: MD Anderson Cancer Center, Houston, Texas
Conditions: Oncologic Complications and Emergencies
Phase 3 Study on the Efficacy and Safety of Human Plasma Derived Antithrombin (Atenativ) in Heparin-Resistant Patients Scheduled to Undergo Cardiac Surgery Necessitating Cardiopulmonary Bypass
Recruiting
The primary objective of this study is to evaluate the efficacy of two different doses of Atenativ, versus placebo, in restoring and maintaining heparin responsiveness in adult patients undergoing cardiac surgery necessitating cardiopulmonary bypass (CPB)
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
06/18/2025
Locations: University of Texas Southwestern Medical Center, Dallas, Texas
Conditions: Acquired Antithrombin Deficiency
An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)
Recruiting
This is a Phase III open-label study to assess if camizestrant improves outcomes compared to standard adjuvant endocrine therapy for patients with ER+/HER2- early breast cancer with intermediate-high or high risk for disease recurrence who completed definitive locoregional therapy (with or without chemotherapy). The planned duration of treatment in either arm within the study will be 7 years.
Gender:
ALL
Ages:
Between 18 years and 130 years
Trial Updated:
06/18/2025
Locations: Research Site, Austin, Texas
Conditions: Breast Cancer, Early Breast Cancer